Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
Background Our understanding of the global scale of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data …
Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data …
Viral persistence, reactivation, and mechanisms of long COVID
The COVID-19 global pandemic caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection has infected hundreds of millions of individuals …
coronavirus 2 (SARS-CoV-2) infection has infected hundreds of millions of individuals …
SARS-CoV-2 variants, vaccines, and host immunity
P Mistry, F Barmania, J Mellet, K Peta… - Frontiers in …, 2022 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
The humoral response and antibodies against SARS-CoV-2 infection
Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
JE Ebinger, J Fert-Bober, I Printsev, M Wu, N Sun… - Nature medicine, 2021 - nature.com
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …
SARS-CoV-2 evolution during treatment of chronic infection
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
critical for virus infection through the engagement of the human ACE2 protein and is a major …
critical for virus infection through the engagement of the human ACE2 protein and is a major …
SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma
Abstract SARS-CoV-2 501Y. V2 (B. 1.351), a novel lineage of coronavirus causing COVID-
19, contains substitutions in two immunodominant domains of the spike protein. Here, we …
19, contains substitutions in two immunodominant domains of the spike protein. Here, we …
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …
Although most randomized controlled trials have shown negative results, uncontrolled …
[HTML][HTML] The first 12 months of COVID-19: a timeline of immunological insights
Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan,
China, in December 2019, the novel coronavirus that causes this disease—severe acute …
China, in December 2019, the novel coronavirus that causes this disease—severe acute …